Prostate cancer is the second most common cancer in men, killing hundreds of thousands each year. However, the current routine screening method for checking prostate-specific antigen (PSA) levels generates false positives in an alarming number of cases, leading to thousands of unnecessary biopsies each year. To combat this, Life Length has developed ProsTAV®, a state-of-the-art in vitro diagnostic test that uses telomere associated variables (TAVs) to identify patients with a higher risk of prostate cancer, aiding screening initiatives and reducing the number of unnecessary biopsies